BMAL1 and cancer: After conducting experiments on the impact of BMAL1 on the sensitivity of certain frrst-line cancer treatment drugs, we observed that knocking down BMAL1 increased the sensitivity of AML cells to the drugs venetoclax, dasatinib, and sorafenib.